BUTENAFINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Butenafine Hydrochloride patents expire, and what generic alternatives are available?
Butenafine Hydrochloride is a drug marketed by Sun Pharma Canada and is included in one NDA.
The generic ingredient in BUTENAFINE HYDROCHLORIDE is butenafine hydrochloride. There is one drug master file entry for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the butenafine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Butenafine Hydrochloride
A generic version of BUTENAFINE HYDROCHLORIDE was approved as butenafine hydrochloride by SUN PHARMA CANADA on November 16th, 2017.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BUTENAFINE HYDROCHLORIDE?
- What are the global sales for BUTENAFINE HYDROCHLORIDE?
- What is Average Wholesale Price for BUTENAFINE HYDROCHLORIDE?
Summary for BUTENAFINE HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 13 |
| Raw Ingredient (Bulk) Api Vendors: | 92 |
| Clinical Trials: | 4 |
| Patent Applications: | 442 |
| DailyMed Link: | BUTENAFINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for BUTENAFINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| United Laboratories | Phase 2 |
| Taro Pharmaceuticals USA | Phase 1 |
Pharmacology for BUTENAFINE HYDROCHLORIDE
| Drug Class | Benzylamine Antifungal |
Anatomical Therapeutic Chemical (ATC) Classes for BUTENAFINE HYDROCHLORIDE
US Patents and Regulatory Information for BUTENAFINE HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma Canada | BUTENAFINE HYDROCHLORIDE | butenafine hydrochloride | CREAM;TOPICAL | 205181-001 | Nov 16, 2017 | OTC | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
